Alex
At Best Startup Canada we track over 100,000 Canadian startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top British Columbia based Vice President operating in the Biotechnology space. If you think a Vice President is missing from this list, feel free to contact our editor on editor@beststartup.ca.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Surjit Dixit
Vice President Technology of Zymeworks
Dr. Dixit is Zymeworks’ Chief Technology Officer, responsible for the implementation of novel algorithms and advancement of the ZymeCAD™ platform. Prior to joining Zymeworks, Dr. Dixit was the coordinator of Computational Molecular Biophysics at Weselyan University, Connecticut, USA, where he was instrumental in the development of novel methods for management and mining of high throughput molecular dynamics simulation data.
Follow Surjit Dixit:
About Zymeworks: Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics.
Edith G. McGeer
Foounder,Vice President & Director of Aurin Biotech
Dr. Edith McGeer is a professor emerita in the Faculty of Medicine at University of British Columbia (UBC). She is the former director of the Kinsmen Laboratory of Neurological Research at UBC. She received her BA from Swarthmore College and her PhD in chemistry from the University of Virginia at the age of 22. She worked for the DuPont Company in Wilmington, Delaware, winning three patents and a citation from the Delaware section of the American Chemical Society before moving with her husband to UBC’s medical school. She has served on the editorial boards of 15 international journals in the neuroscience field. She has recently been on numerous scientific review boards, particularly for the National Institutes of Health (NIH) in the United States, and was one of the initial members of the Executive Committee of the World Federation of Neurology Group on the Dementias. She is an Officer of the Order of Canada, a Fellow of the Royal Society of Canada, a member of the Order of British Columbia and the recipient of three honorary degrees. She is the author of 525 scientific articles, 10 patents, an author of the textbook Molecular Neurobiology of the Mammalian Brain with her husband Dr. Patrick McGeer and Sir John Eccles. The McGeers were both original members of the Highly Cited Researchers database of the ISI, being among the world’ top 100 most highly cited neuroscientists.
Follow Edith G. McGeer:
About Aurin Biotech: Aurin Biotech Inc. is a private company established to advance the development of a remarkable collection of small molecules.
Patrick Foody
Executive Vice President, Advanced Biofuels of Iogen
Patrick Foody is the executive vice president for advanced biofuels at Iogen.
Follow Patrick Foody:
About Iogen: Iogen creates technology to render agricultural residues and other organic waste clean burning, renewable cellulosic biofuels.
Mei Mei Tian
Vice President, Head of External Research of Bioasis Technologies
Mei Mei Tian is the VP & Head of External Research at Bioasis Technologies, Inc.
Follow Mei Mei Tian:
About Bioasis Technologies: Bioasis Technologies, Inc. is a biopharmaceutical company.
Michelle Seltenrich
Vice President of Operations of Sirona Biochem
Michelle Seltenrich brings 15 years of experience in publicly traded biotech companies. Her experience ranges from pharmaceutical lab management to corporate development in mergers/acquisitions. Ms. Seltenrich was previously Manager of Business Development at Forbes MediTech and was responsible for international business development, in-licensing and M&A. She worked with senior management in M&A recommendation and played a key role in the successful acquisition of a U.S. based biotech company. Ms. Seltenrich holds a BSc from the University of British Columbia and an MBA in Technology Management from Simon Fraser University.
Follow Michelle Seltenrich:
About Sirona Biochem: Sirona Biochem is a biotechnology company developing diabetes therapeutics, as well as skin depigmenting and anti-aging agents.
Nicole Ranger
Vice President of Engineering & Product Development of Pyng Medical
A Professional Engineer, Nicole brings over 17 years of experience in managing and developing product lines from concept to market, with over 9 years in the medical device industry. Since joining Pyng Medical, Nicole has led product development and enhancement projects, contributing significantly to Pyng Medical’s first reaching profitability. Prior to joining Pyng Medical, Nicole held R&D, engineering, project and product management roles in the medical device, sports equipment and bioengineer industries. She is responsible for developing over a dozen products now in the marketplace and is named in four patents. Nicole holds a Bachelor of Applied Science (Mechanical Engineering) from the University of Toronto as well as a Bachelor of Science (Honours Kinesiology) from the University of Waterloo.
Follow Nicole Ranger:
About Pyng Medical: Pyng Medical develops trauma and resuscitation products for the health care industry.
Michael Lyle
Vice President – Research and Development of Welichem Biotech
Dr. Lyle joined the company in 2006 as a medicinal chemist working on our early stage drug development programs in inflammatory diseases and cancer. From there he became the Head of Chemistry in 2008 and the VP of Research and Development in 2010. Dr. Lyle played an integral role in the development of WBI1001 and these efforts ultimately culminated in the $230M acquisition of WBI1001 by GSK in July 2012. Dr. Lyle holds a PhD in Chemistry from Simon Fraser University (SFU) and has authored numerous peer-reviewed scientific publications and patents.
Follow Michael Lyle:
About Welichem Biotech: Welichem Biotech is a development stage biotechnology company, engages in the discovery and development of therapeutic drugs.
Bruce Reese
Vice President of Finance of Apteryx Imaging
Follow Bruce Reese:
About Apteryx Imaging: Apteryx Imaging develops tissue fluorescence visualization technologies.
Peter Haughton
Vice President of Australia/Asian Sales of Agro Epigenetics Corp
Peter has been instrumental in developing relationships with China and Australia to further the interests in AEC’s polyploidy seed technology.
Follow Peter Haughton:
About Agro Epigenetics Corp: Agro Epigenetics Corp is a canadian biotechnology company.
Jason Crawford
Vice President, Scientific Operations of Centre for Drug Research and Development
As the Vice-President of Scientific Operations at The Centre for Drug Research and Development (CDRD), Canada’s fully-integrated national drug development and commercialization centre, Jason plays a key role in the evaluation of potential drug development projects to be incubated within CDRD, and holds responsibility for the successful execution of all subsequent project development plans, and thus the overall management of CDRD’s scientific resources. Prior to assuming this role, he was Head of Medicinal Chemistry at CDRD, having joined the organization in 2008. Previously, from 1999-2007, he held a series of increasingly-senior positions at AnorMED Inc. – initially a Medicinal Chemist, and eventually the Manager of the Development Chemistry Group, leading the synthetic development of all lead and candidate compounds intended for use in pre-clinical and clinical trials. Notably, for plerixafor, which now generates over $150 million annually in global sales as Mozobil, he oversaw the technical transfer of the development process to a contract research organization, the subsequent clinical manufacture, and the eventual validation of the manufacturing process for commercial use. He also acted concurrently as an interdisciplinary project team leader for a clinical-stage anti-HIV therapeutic.
Follow Jason Crawford:
About Centre for Drug Research and Development: The Centre for Drug Research and Development (CDRD) is Canada’s national drug development and commercialization engine.
GIPHY App Key not set. Please check settings